Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Kinetik Holdings heads into its November earnings with short interest rising sharply, a 10%-plus holder selling daily, and analysts nudging targets higher despite the stock trading at a premium to most of the Street's calls.
The dominant story this week is the short interest build. Short positions climbed nearly 20% in the past week to 11.5% of the free float, a level ORTEX classifies as high. The rise accelerated around October 7 to 8, when short shares jumped from roughly 6.2 million to 6.3 million before climbing further to 7.4 million by week's end. That is a 23.6% increase over the past month. The borrow market, however, tells a different story about conviction. Availability remains extremely loose at 758%, meaning there are roughly 36 million shares available to lend against the 7.4 million currently borrowed. Cost to borrow is 0.52%, down nearly 9% on the week and a fraction of the levels seen in early September, when it briefly reached 1.07%. Short sellers have taken on meaningful exposure but face no squeeze pressure: the lending pool is wide open and cheap.
Options positioning offers no directional signal worth leaning on. The put/call ratio is 0.20, almost exactly in line with its 20-day average and nowhere near its 52-week high of 0.68. That range itself is narrow. The PCR has barely moved in a month, suggesting options traders are not expressing a strong view either way into the November 4 earnings event.
Analysts have turned more constructive in the past two days. RBC Capital raised its target to $58 on October 14, maintaining an Outperform rating. Barclays moved its target up to $56 from $51 the day before, keeping an Equal-Weight call. Both moves follow a string of upgrades post the August print, when Morgan Stanley lifted its target to $70 and Truist pushed to $59. The consensus mean target is $58.19, modestly above the current price of $55.55. The EV/EBITDA multiple is running near 9.9x, roughly flat over the past month. Factor scores paint a split picture: EPS momentum and surprise are in the top 5 to 8% of the ORTEX universe, and the dividend score ranks at the 98th percentile, while the short score rank sits in the 11th percentile, reflecting the elevated and rising short interest.
The bull case rests on Permian volume recovery. Waha prices have stabilised, Kings Landing II and the ECCC Pipeline expand capacity, and the company boosted its 2026 adjusted EBITDA guidance to between $1.04 billion and $1.1 billion. More than 80% of gross margin is fixed-fee, giving revenue visibility even when basin activity softens. Bears point to the same geography as the risk: Permian-only exposure means adverse weather, water shortages, or a crude price drop can hit volumes hard, and more integrated rivals can bundle fractionation and export services that Kinetik cannot match independently.
The most newsworthy data point this week is not the short interest build but what may be driving it. ISQ Global Fund II GP LLC, which holds an 18.4% stake on a Schedule 13D filing and therefore an activist position on the register, has been selling continuously. From October 5 through October 12, ISQ sold shares on every trading day, accumulating roughly $20.8 million in disposals over that stretch. Its 90-day net selling across all insider activity totals $105.6 million. These are open-market sales, not part of a 10b5-1 plan. ISQ's stake has slipped from 18.9% to 18.4% as disclosed on September 21, and further sales since then will have compressed it further. Activist disclosures are event-driven around the 5% threshold: positions are as-last-disclosed and a holder dropping below 5% may never file again. For now, ISQ remains on the 13D register, but the selling cadence is consistent and heavy.
ORTEX also flags that KNTK is a candidate for the December 2026 Russell Semi-Annual Review. ORTEX puts the probability of a Russell 1000 addition and corresponding Russell 2000 deletion at 25% each. The price that decides it is $61.20 to qualify for the larger index, a 10.2% move from current levels. The rank date is October 30. If the addition were confirmed, index trackers would need to buy approximately $154 million of stock, or about 2.4 days of normal volume. The deletion side carries the larger mechanically driven flow: $417 million of forced selling, or 6.5 days of volume. Neither is confirmed; both are probabilities that hinge on where the stock closes around the rank date.
Midstream peers had a constructive week. TRGP rose 2.6%, OKE added 4.7%, and KMI gained 3.9%. KNTK's 3% weekly gain kept pace broadly but lagged OKE and KMI. AM was the outlier, slipping 0.3%.
What to watch over the next three weeks: October 30 is the Russell rank date, the anchor for whether the index rebalance probability moves materially in either direction; and November 4 is the earnings date, where the two prior prints both produced positive 1-day and 5-day moves, giving the stock a consistent post-results pattern but no guarantee of a repeat.
See the live data behind this article on ORTEX.
Open KNTK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
